Paloma Partners’s Harvard Bioscience HBIO Stock Holding History

Paloma Partners’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-16,170	Closed	-$323K	–	2079
2019 Q2	$323K	Buy	+16,170	New	+$474K	0.01%	1255
2016 Q3	–	Sell	-12,529	Closed	-$359K	–	1948
2016 Q2	$359K	Buy	+12,529	New	+$399K	﹤0.01%	1694
2014 Q3	–	Sell	-11,558	Closed	-$526K	–	1140
2014 Q2	$526K	Buy	+11,558	New	+$486K	0.02%	560

Other funds holding HBIO

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Paloma Partners's HBIO Position: Q3 2019 in Review

Paloma Partners sold out of Harvard Bioscience (HBIO) in Q3 2019, closing a stake of 16,170 shares — an estimated $323K sold.

Paloma Partners first reported a position in HBIO in Q2 2014 and held it in 3 quarters. The position peaked at $526K in Q2 2014. 71 funds tracked by Wall St. Rank hold HBIO as of Q3 2019.

Paloma Partners reported no remaining Harvard Bioscience position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 16,170 Harvard Bioscience shares in Q3 2019, an estimated $323K.
Paloma Partners first reported a position in Harvard Bioscience in Q2 2014 and held it in 3 quarters.
Paloma Partners's Harvard Bioscience position peaked at $526K in Q2 2014.
71 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.